The Blubber

Every day, Unusual Whales will be doing sector news for the week, sponsored by an advertiser.

Today is biotech, sponsored by $PETV!

• BMY has earnings today
• RCKT can quadruple per Cantor Fitzgerald
• BIVI presenting data end of Oct
• PETV released PR that they received a response at the 2023 Veterinary Surgeons Conference
• DHR, CBAY, HCA received buy ratings from analysts, while MEDP, TMP, and TDOC received hold ratings
• ACIU presenting next trial data
• AXSM trial on Oct 27th
• INMB has Oct 27th FDA discussions, QURE reports data
• APTO presentation

Other news includes $BIIB presenting new clinical data on Alzheimers, $ALNY presenting on amyloidsis, and $AKBA resubmitting a new drug application.

PETV, the sponsor of today's sector news, noted that their SPRYNG osteoarthritis treatment received feedback at the conference.

The following is directly from their press release, here:

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it received a very favorable response from veterinarians regarding the Company’s innovative product Spryng^™, with OsteoCushion^™ technology at the American College of Veterinary Surgeons (“ACVS”) conference held on October 11^th to October 14^th, 2023 in Louisville, Kentucky.

SPRYNG^™ with OsteoCushion^™ Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.

Two presentations at the ACVS Conference heightened the enthusiastic interest in veterinarians to learn more about Spryng and consider its use in their practices. The first presentation was given to an overflowing hall of veterinarians by Jessica Rychel, DVM, DACVSMR and Lindsey M. Fry, DVM, DACVSMR, CVPP, CCRP, cVMA, DVM, DACVSMR, CCRP, CVPP, cVMA, both founders of Red Sage Integrative Veterinary Partners; this presentation was entitled “When Surgery is Not an Option- a Multimodal Approach to Management of Orthopedic Cases”. Joseph Manning, DVM, and Senior Technical Veterinarian for the Company, gave the second presentation related to the use of Spryng^™ with OsteoCushion^™ Technology entitled “Advancements in Intra-Articular Therapies: A Naturally Derived Option for Joints”.

Finally, the Company released the completed results of a clinical study conducted by Ethos Veterinary Health at the ACVS annual conference; the clinical study examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng^™ with OsteoCushion^™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM presented the clinical study poster at the ACVS Conference. The clinical study results demonstrated that there were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring). In summary, this study demonstrated that Spryng^™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease (“CCD”) when patient and/or owner factors preclude surgical intervention. To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following:

https://www.sprynghealth.com/acvs-2023-poster-presentation?fbclid=IwAR3VuoyNy8wdqFnnArkNsjI-HzTXtXo49jDI3WOn8-835jMBf5spy451O6E

“The ACVS Conference provided us an excellent forum to demonstrate to leading veterinary surgeons our innovative medical device, Spryng, with OsteoCushion Technology, for the management of osteoarthritis” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The conference resulted in us achieving our main objective, which was to explain to veterinarians that Spryng could be considered for first-line therapy in any animal, including those animals not able or willing to take oral medications and those not able or willing to undergo surgery.”

For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.

Note: This post was sponsored by $PETV, PetVivo, and UW was paid to promote. Unusual Whales, through the third party Unusual Relations, does not encourage purchasing based on promotion. Unusual Whales does not recommend using the information as advice for portfolios. Do not follow a sponsor due to any one post.

Note: This post was conducted on behalf of PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) and was funded by Outside The Box Capital Inc. and/or affiliates after UNUSUAL RELATIONS Inc. was engaged by Outside The Box Capital Inc. to advertise for PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW). For our full disclaimer, please visit: unusualwhales.com/terms

To see all news at it comes in, check Unusual Whales, https://unusualwhales.com/news-feed?limit=100&search_term=health